FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2361-2363 November 30, 2006 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Belfort, R. PubMed Citation

Mostly unrecognized before 1980, nonalcoholic fatty liver disease now affects all fields of clinical medicine and is the most common form of chronic liver disease in the United States.¹ The prevalence of this disorder is expected to increase with the epidemic of obesity and type 2 diabetes mellitus. Its prevalence in non-Western countries is also increasing,² in large part because of globalization of the Western diet. Data based on ultrasonographic studies and serum enzyme measurements indicate that the prevalence of nonalcoholic fatty liver disease in the general U.S. population is approximately 30%.^1,3 This suggests that there may be as many . . . [Full Text of this Article]

Source Information

From the Department of Gastroenterology and Hepatology, Cleveland Clinic, and the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University — both in Cleveland.

This article has been cited by other articles:

• Anderson, N., Borlak, J. (2008). Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacol. Rev. 60: 311-357 [Abstract] [Full Text]